165 related articles for article (PubMed ID: 17008166)
1. Clinical approaches involving thrombopoietin to shorten the period of thrombocytopenia after high-dose chemotherapy.
Tijssen MR; van der Schoot CE; Voermans C; Zwaginga JJ
Transfus Med Rev; 2006 Oct; 20(4):283-93. PubMed ID: 17008166
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human thrombopoietin: clinical experience and in vivo biology.
Vadhan-Raj S
Semin Hematol; 1998 Jul; 35(3):261-8. PubMed ID: 9685172
[TBL] [Abstract][Full Text] [Related]
3. Long-term platelet production assessed in NOD/SCID mice injected with cord blood CD34+ cells, thrombopoietin-amplified in clinical grade serum-free culture.
Mattia G; Milazzo L; Vulcano F; Pascuccio M; Macioce G; Hassan HJ; Giampaolo A
Exp Hematol; 2008 Feb; 36(2):244-52. PubMed ID: 18023520
[TBL] [Abstract][Full Text] [Related]
4. The efficacy of recombinant thrombopoietin in murine and nonhuman primate models for radiation-induced myelosuppression and stem cell transplantation.
Wagemaker G; Neelis KJ; Hartong SC; Wognum AW; Thomas GR; Fielder PJ; Eaton DL
Stem Cells; 1998; 16(6):375-86. PubMed ID: 9831863
[TBL] [Abstract][Full Text] [Related]
5. Physiologic role of TPO in thrombopoiesis.
Miyazaki H
Stem Cells; 1996; 14 Suppl 1():133-8. PubMed ID: 11012213
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human thrombopoietin (rhTPO) after autologous bone marrow transplantation: a phase I pharmacokinetic and pharmacodynamic study.
Wolff SN; Herzig R; Lynch J; Ericson SG; Greer JP; Stein R; Goodman S; Benyunes MC; Ashby M; Jones DV; Fay J
Bone Marrow Transplant; 2001 Feb; 27(3):261-8. PubMed ID: 11277173
[TBL] [Abstract][Full Text] [Related]
7. [Clinical use of recombinant human thrombopoietin. Status and perspectives].
Hansen PB; Hasselbalch HC
Ugeskr Laeger; 2001 May; 163(19):2659-62. PubMed ID: 11360368
[TBL] [Abstract][Full Text] [Related]
8. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura.
Newland A
Semin Hematol; 2007 Oct; 44(4 Suppl 5):S35-45. PubMed ID: 18096471
[TBL] [Abstract][Full Text] [Related]
9. An effective and simple expansion system for megakaryocyte progenitor cells using a combination of heparin with thrombopoietin and interleukin-11.
Feng Y; Zhang L; Xiao ZJ; Li B; Liu B; Fan CG; Yuan XF; Han ZC
Exp Hematol; 2005 Dec; 33(12):1537-43. PubMed ID: 16338497
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human thrombopoietin clinical development.
Jones DV; Ashby M; Vadhan-Raj S; Somlo G; Champlin R; Gajewski J; Hellmann S; Fyfe G
Stem Cells; 1998; 16 Suppl 2():199-206. PubMed ID: 11012192
[TBL] [Abstract][Full Text] [Related]
11. Thrombopoietin: Biology and Clinical Applications.
Kuter DJ
Oncologist; 1996; 1(1 & 2):98-106. PubMed ID: 10387974
[TBL] [Abstract][Full Text] [Related]
12. Cytokines for the treatment of thrombocytopenia.
Ciurea SO; Hoffman R
Semin Hematol; 2007 Jul; 44(3):166-82. PubMed ID: 17631181
[TBL] [Abstract][Full Text] [Related]
13. AKR-501 (YM477) a novel orally-active thrombopoietin receptor agonist.
Fukushima-Shintani M; Suzuki K; Iwatsuki Y; Abe M; Sugasawa K; Hirayama F; Kawasaki T; Nakahata T
Eur J Haematol; 2009 Apr; 82(4):247-54. PubMed ID: 19183407
[TBL] [Abstract][Full Text] [Related]
14. The role of recombinant interleukin 11 in megakaryocytopoiesis.
Turner KJ; Neben S; Weich N; Schaub RG; Goldman SJ
Stem Cells; 1996; 14 Suppl 1():53-61. PubMed ID: 11012203
[TBL] [Abstract][Full Text] [Related]
15. Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?
Hofmann WK; Ottmann OG; Hoelzer D
Leukemia; 1999 Jan; 13(1):14-8. PubMed ID: 10049050
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy-induced thrombocytopenia derives from the selective death of megakaryocyte progenitors and can be rescued by stem cell factor.
Zeuner A; Signore M; Martinetti D; Bartucci M; Peschle C; De Maria R
Cancer Res; 2007 May; 67(10):4767-73. PubMed ID: 17510405
[TBL] [Abstract][Full Text] [Related]
17. Thrombopoietin: biology and potential clinical applications.
Prow D; Vadhan-Raj S
Oncology (Williston Park); 1998 Nov; 12(11):1597-604, 1607-8; discussion 1611-4. PubMed ID: 9834938
[TBL] [Abstract][Full Text] [Related]
18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
19. Memorial lecture. Megakaryocytic growth factors: is there a new approach for management of thrombocytopenia in patients with malignancies?
Hofmann WK; Ottmann OG; Hoelzer D
Leukemia; 1999 Apr; 13 Suppl 1():S14-8. PubMed ID: 10232362
[TBL] [Abstract][Full Text] [Related]
20. [The clinical study of recombinant human thrombopoietin in the treatment of chemotherapy-induced severe thrombocytopenia].
Bai CM; Zou XY; Zhao YQ; Han SM; Shan YD;
Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):397-400. PubMed ID: 15061993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
